Skip to main
  1. Stocks
  2. Harvard Bioscience
  3. Forecast
HBIO

Harvard Bioscience (HBIO) Stock Forecast & Price Target

Harvard Bioscience (HBIO) Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Harvard Bioscience is attractive on fundamentals because 2Q revenue of $22.7 million beat expectations, and full-year 2026 revenue growth guidance was raised to 3-5% while Adjusted EBITDA growth of 6-10% was reaffirmed. Its new product innovation pipeline is gaining traction, with NPI contributing about 11% of 2Q revenue and targeted to reach 15-20% in 2027, supported by strong sales in the Americas up 13% and China up 29%. In addition, Project Viking is on track to generate $3 million of cost savings in 2027 and $4 million in 2028, with restructuring substantially complete by 1Q 2027, supporting margin expansion and balance sheet delevering.

Bears say

Harvard Bioscience is facing a weaker fundamental setup because 3Q results only met expectations while management lowered the 2026 EBITDA target, citing a less favorable mix toward lower-margin CMT products and more distribution and China revenue. Although biopharma demand and NPI platforms such as SoHo, MeshMEA, and BTX support longer-term innovation, the investment case is constrained by a 12% WACC, a 49% debt-to-capital ratio, and operating and EBITDA margins that do not justify multiple expansion. The outlook is further pressured by restructuring and consolidation risks from Project Viking, heightened FDA and regulatory uncertainty, exposure to NIH and other funding cycles, and currency and competitive pressures that could disrupt execution.

Harvard Bioscience (HBIO) has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harvard Bioscience and is not a guaranteed prediction by Public.com or investment advice.

Harvard Bioscience (HBIO) Analyst Forecast & Price Prediction

Get the latest Harvard Bioscience (HBIO) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Harvard Bioscience (HBIO)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harvard Bioscience (HBIO) Forecast

Analysts have given Harvard Bioscience (HBIO) a Buy based on their latest research and market trends.

According to 1 analysts, Harvard Bioscience (HBIO) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harvard Bioscience (HBIO)


Harvard Bioscience (HBIO) Analyst Forecast & Price Prediction

Get the latest Harvard Bioscience (HBIO) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Harvard Bioscience (HBIO)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover HBIO stock data and trends